Resistance to azoles and echinocandins has emerged as a significant factor affecting the clinical management of patients with invasive fungal infections. Immunosuppressed patients at high risk for invasive fungal infections often have prolonged or repeated exposure to antifungals resulting in either the well-documented selection of naturally occurring, less susceptible fungal species, or the in situ development of specific resistance mechanisms. Nucleic acid-based molecular diagnostics are particularly well suited for the rapid detection of low-abundance fungal pathogens and identification of the infecting pathogen to the genus and species levels, as well as assessment of resistance mechanisms. A wide range of molecular probing technologies involving real-time polymerase chain reaction (PCR) assays that facilitate direct analysis of a single infecting genome in a sterile blood specimen are available and have recently been commercialized (eg, Roche LightCycler SeptiFast and T2 Biosystems T2Candida). One of the exciting applications of molecular technology is the direct detection of specific resistance mechanisms that evolve during therapy. In principle, the detection of resistance mechanisms that have been independently validated to cause resistance provides a culture-independent biomarker for potential therapeutic failure. The emergence of real-time PCR assays utilizing allele-specific molecular detection technology that is highly sensitive, robust, and high-throughput has the potential to improve patient care by providing faster detection of drug-resistant infecting strains and to help inform therapeutic management.
Laboratory diagnostics provide critical information to medical professionals so that better-informed decisions can be made regarding patient care. However, many current methods for the diagnosis of invasive infections, including those caused by bacteria and fungi, are limited by the time it requires for the laboratory tests to be completed. For example, bloodstream infections are typically diagnosed through a series of blood cultures followed by post-blood culture species identification and susceptibility testing. This strategy has substantial diagnostic limitations that can lead to delays in appropriate therapy and the incurrence of unnecessary healthcare expenses. Without the ability to rapidly identify pathogens, physicians typically start empiric treatment of at-risk patients with broad-spectrum antibiotics and antifungals. This approach may contribute to increased morbidity and mortality due to toxicities and drug interactions that can occur with some antimicrobials, as well as contribute to the development and spread of antimicrobial resistance. In addition, it is well documented that delays in the initiation of appropriate therapy can lead to increased mortality [1] [2] [3] . Thus, rapid and sensitive diagnostic assays for both the identification of the infecting pathogen and detection of resistance can help maximize positive patient outcomes.
CURRENT METHODS FOR PATHOGEN IDENTIFICATION AND DETECTION OF ANTIFUNGAL RESISTANCE
The current standard for identifying fungal infections requires a lengthy and labor-intensive analysis, which begins with the culturing of a biological fluid (eg, blood) or tissue. For blood cultures, a large volume of blood is required (≥20 mL) and is placed into bottles containing nutrients formulated for growth of microbes. Growth of the infecting organism may take a period of days due to the low initial concentration of the pathogen within the collected specimen (often <10 colony-forming units [CFU]/mL). Once positive growth is detected, additional time is required to culture and grow the pathogen on solid growth media and perform species identification. If antifungal susceptibility testing is requested, additional time is needed to complete these assays, and each of the current methods requires a pure culture. Thus, identification of the infecting pathogen and determining that it may be resistant to certain antifungals is a time-consuming process, which can further lead to delays in appropriate therapy. However, identification of the infecting organism to the species level, combined with local antibiogram data in the absence of susceptibility results, can be informative for making treatment decisions [4] [5] [6] .
Susceptibility testing is used clinically to determine the in vitro potency of antimicrobial agents against an infecting pathogen. Currently, antifungal susceptibility testing is performed by phenotypic assays, such as the Clinical and Laboratory Standards Institute (CLSI) and European Union Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods, variations of these that use colorimetric endpoints (eg, YeastOne Sensititre assay), agar-based methods that use concentration gradients of antifungals that diffuse into the growth media (eg, Etest), or via automated means (eg, Vitek 2) [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Upon completion of testing, a minimum inhibitory concentration (MIC) value is obtained, and this is used to classify the infecting isolate as susceptible or resistant to different antifungals. This is done by correlating MICs with in vivo efficacy results from either animal models or, more ideally, from clinical studies to help predict the outcome of therapy with a particular drug [5, 6, 17] . However, correlations between in vitro susceptibility results and clinical outcomes are not available for many fungal pathogens. This includes both yeasts (eg, Cryptococcus species) and molds (eg, Fusarium species and members of the order Mucorales) [18, 19] . In addition, the mechanisms of resistance for many species are not well understood.
Antifungal susceptibility testing is now recommended for the azoles against all bloodstream and other clinically relevant Candida isolates, and for the echinocandins against Candida glabrata and Candida parapsilosis isolates [20] . It is important to remember that several factors other than in vitro potency of a drug influence clinical outcomes, including host immune response, severity of the underlying disease and other comorbidities, and antifungal exposures achieved at the site of infection [4] [5] [6] . Thus, a susceptible result or low MIC value from in vitro testing does not necessarily predict a positive response to treatment. Similarly, an elevated MIC does not automatically predict treatment failure, although the chances of poor outcomes are higher when in vitro resistance is observed [5, 6, 17] .
Although antifungal susceptibility testing can provide useful information to clinicians to help guide therapy, these phenotypic methods have several limitations. In addition, a pure culture of the infecting organism is needed to perform susceptibility testing by the currently available methods. Thus, they cannot be used to detect resistance in culture-negative infections. Clinical breakpoints, the MIC thresholds used to classify isolates as susceptible or resistant, are only available for certain species of fungi, and in the United States, the CLSI has not set breakpoints against any molds, including Aspergillus species. In addition, significant interlaboratory variability has been reported for the echinocandin caspofungin when broth microdilution methods are used [21] [22] [23] [24] , possibly leading to falsely high intermediate or resistant classification rates by some laboratories. Because of this variability, EUCAST does not recommend susceptibility testing with caspofungin, but instead using anidulafungin and micafungin MICs as surrogate markers to predict susceptibility or resistance to caspofungin [23] . The usefulness of anidulafungin and micafungin MICs as surrogate markers for caspofungin resistance has also been demonstrated with the CLSI broth microdilution method [25, 26] .
New Technologies for Rapid Identification to the Species Level Including

Culture-Negative Molecular Assays
Identification of the infecting organism to the species level can be combined with local antibiogram results to help guide therapy. However, as with antifungal susceptibility testing, species-level identification can be a time-consuming process. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) is now being used by many clinical microbiology laboratories for the rapid species identification of bacteria and yeasts [27] [28] [29] [30] . This technology, which uses the detection of mass-to-charge ratios of ribosomal proteins that are highly conserved among isolates of the same species and the comparison of the measured spectra to known spectra within a database, significantly reduces the turnaround time compared to biochemical and molecular techniques, such as DNA sequence analysis. Currently, MALDI-TOF requires a pure culture in order for the assay to be performed. Although some studies have reported success with the identification of pathogens from direct specimens and positive blood-culture bottles by MALDI-TOF, this is not widely used by clinical laboratories, and MALDI-TOF susceptibility testing methods have not been assessed on direct specimens.
Direct-draw assessment of primary specimens can be achieved with various nucleic acid amplification methodologies (eg, polymerase chain reaction [PCR], nucleic acid sequence-based amplification [NASBA]). In principle, these detection approaches are highly sensitive (1-10 CFU) because they target high-copy ribosomal genes, which provide genusand species-level pathogen identification [31, 32] . Nucleic acid amplification can also target resistance-associated genes, although such detection is generally less sensitive because such genes are often found in single or low copy in the genome. For most nucleic acid diagnostics, there is a requirement for extraction of nucleic acid from target cells of a clinical sample. Extraction is an inefficient process and 90% or more of cells may be lost [33] . Such extractions may be further complicated by host nucleic acid, as well as associated noninfecting organisms. Once nucleic acid is extracted, DNA sequencing is the "gold standard" for all molecular evaluations, especially in reference laboratories. However, DNA sequencing is not always a practical solution for many clinical laboratories. Realtime PCR (DNA amplification) or NASBA (RNA amplification) approaches utilizing a variety of allele-specific detection technologies (eg, TaqMan, Molecular Beacons) allow for rapid assessment of pathogen-specific nucleic acid. These assays are highly sensitive and can detect 1-5 genome copies of a target genetic element [34, 35] . Commercial PCR tests such as the Roche LightCycler SeptiFast kit can be used to rapidly identify a variety of Candida species, including C. albicans, C. glabrata, C. krusei, C. parapsilosis, and C. tropicalis. However, this assay is not currently available for use in the United States.
Recently, T2 Biosystems introduced the T2Dx instrument, which combines nuclear magnetic resonance spectroscopy with PCR for the direct detection of Candida species within whole blood [36, 37] . Following lysis of red blood cells, Candida cells are lysed and DNA is amplified using pan-Candida primers directed for the ITS2 region. Hybridization of the amplified DNA then occurs to supramagnetic nanoparticles that agglomerate, and a T2 magnetic resonance measurement is made. This assay has excellent analytical sensitivity, with ranges of 1-3 CFU/mL for the common Candida species that it detects (C. albicans/C. tropicalis, C. glabrata/C. krusei, and C. parapsilosis) [36] [37] [38] . In addition, excellent clinical specificity (99.4%) has also been reported, and results are available within hours compared to days for traditional blood culture analysis [37] . Thus, these results can be paired with negative results to stop unnecessary antifungal therapy, or positive results with local antibiogram data to help guide therapy.
PROTENOMIC AND MOLECULAR DIAGNOSTICS FOR DETECTION OF ANTIFUNGAL RESISTANCE
MALDI-TOF technology can lead to more rapid species identification, thus helping to improve the selection of appropriate treatment regimens. Some groups have also begun to evaluate MALDI-TOF as a means of drug susceptibility testing against bacteria and Candida species [39] [40] [41] [42] [43] . It is known that the protein composition of Candida isolates will vary when exposed to antifungal drugs [44] . This may be part of compensatory responses occurring in response to environmental stresses, and the composition may differ between susceptible and resistant isolates. Thus, this may lead to more rapid identification of the infecting species and resistance detection. Studies have reported good categorical agreement between results obtained by MALDI-TOF susceptibility testing methods and the CLSI reference method [41, 45] , although such results have not been found by all [43] . It should be noted that other factors may also influence protein composition, and these in turn could also affect MALDI-TOF antifungal susceptibility results. In addition, culture independence with this technology has not yet been achieved, as the studies to date that have evaluated MALDI-TOF for susceptibility testing have done so using pure cultures.
Molecular diagnostics are ideally suited for resistance detection provided that the resistance mechanism has been clinically validated. In fungi, resistance to the major antifungal classes, the echinocandins, azoles and polyenes, often result from chromosomal changes, including mutations that alter the drug target or induction of efflux pumps. As these genes are present in low copy (1N or 2N) , PCR amplification is critical. Similar to clinical breakpoint determinations, a genetic target with a validated mechanism resistance should confer (1) an elevated MIC in standardized susceptibility testing; (2) an altered drug target interaction or effector action (eg, transcription factor); (3) dose-dependent resistance in pharmacodynamic animal models; and (4) documented clinical failures. These features are best represented in echinocandins with Candida species and azoles with Aspergillus fumigatus.
Echinocandin Resistance and Molecular Assays
The mechanism of echinocandin resistance is well established to involve a limited number of amino acid substitutions in highly conserved "hot spot" regions of the Fks subunits, which comprise the catalytic region of glucan synthase [46] . Unlike the azoles, echinocandins are not subject to the action of common multidrug transporters [47] . These amino acid substitutions within Fks subunits decrease the sensitivity of enzyme to drug, in some cases by several thousand-fold, resulting in higher MIC values and treatment failures [48] [49] [50] . Relative drug resistance phenotypes vary depending on the nature of the amino acid substitution, and associated clinical responses are reflected in pharmacodynamic models [51, 52] . In most Candida species, there are 3 FKS genes: FKS1, FKS2, and FKS3. Mutations in FKS1 alone account for resistance in all Candida species, except the haploid organism C. glabrata where mutations in both FKS1 and FKS2 confer resistant phenotypes [53, 54] . Only a few mutations account for 65%-80% of observed echinocandin clinical resistance. In C. albicans, amino acid substitutions at amino acid positions Fks1p-S641 and Pfs1p-S645 account for nearly 90% of resistant organisms [55] . In C. glabrata, 88% of echinocandin-resistant strains showed substitutions at the Fks1p-F625, Fks1p-S629, Fks1p-D632, Fks2p-F659, and Fks2p-S663 residues (Figure 1) [56, 57] . The large body of data associating the presence of highly limited FKS mutations with diminished echinocandin therapeutic response and clinical outcome raises the possibility that molecular testing may provide a surrogate for resistance phenotypes [34] . Molecular assays are capable of resolving all known FKS mutations associated with drug resistance in C. albicans and C. glabrata within 3-4 hours. In addition, when used in conjunction with molecular evaluation of primary species identification, they provide a rapid genotypic assessment of the echinocandin resistance potential for infecting strains. As long as specific mutations are known and validated, the assays can be readily extended to other Candida species.
Although DNA sequencing is highly informative and accurate, targeted gene sequencing is impractical for most routine clinical microbiology laboratories. In response, real-time PCR assays capable of allele discrimination (sequencing probes) have been developed to distinguish FKS hot spot mutations from wild-type, and several studies have been published describing these. Baslashov et al first described a real-time multiplexed molecular beacon (MB) probe detection system that could distinguish changes in the codon for position Ser645 in C. albicans [58] . Mutations at this locus were reliably identified in both the heterozygous and homozygous states, and the assay was used to evaluate 2 large collections of spontaneous resistant mutants from different strain backgrounds. To address resistance among C. glabrata strains, Pham et al described a microsphere-based assay using Luminex MagPix technology along with asymmetric PCR to identify prominent mutations in hot spot 1 (HS1) of both FKS1 and FKS2 [59] . The multiplexed assay was initially validated using 102 isolates, which were previously characterized by DNA sequencing. It was further utilized to accurately screen 1032 C. glabrata surveillance isolates. More recently, a multiplexed MB and melt-curve assay was described by Zhao et al [60] . Unlike conventional PCR, this assay distinguishes between closely related genotypes using asymmetric PCR and melting curve analysis. The temperature at which the probe-target hybrids melt apart (Tm) varies as the target changes from a perfectly matched sequence to mismatched sequence. A dual assay for C. glabrata FKS1 and FKS2 rapidly identified within 3 hours the most prominent and clinically relevant resistance-associated mutations in FKS1 HS1 (WT, S629P, F625S F659del, F659S, F659V, F659L, S663P, S663F ) genotypes. A blinded panel of 188 C. glabrata clinical isolates was tested, and this assay was shown to have 100% concordance with DNA sequencing (Figure 2) . Finally, Dudiuk et al described an inexpensive, simple, and quick assay using classical PCR primer sets for wild-type and resistant (mutant) sequences to detect the 10 most common mutations in C. glabrata within 4 hours [56] . While these promising assays can rapidly identify echinocandin resistance mechanisms, they have currently been evaluated using cultures and not direct specimens. Thus, additional work is needed to apply these assays to direct specimens to further decrease the time to detection of echinocandin resistance. Such work is needed as data has emerged demonstrating that the presence of FKS mutations in C. glabrata isolates collected from patients with previous echinocandin exposure is highly predictive of treatment failure [61] .
Azole Resistance and Molecular Assays
Acquired azole resistance in Candida species is multifaceted, including up-regulation of drug transporters, overexpression and/or alteration of the drug target, and cellular stress response factors [62] . The induction of drug efflux pumps, encoded by Distribution of 186 blind-tested clinical strains with specific Fks1 hot spot amino acid substitutions determined by melt curve analysis to distinguish between wild-type (WT) and resistance-associated alleles [60] .
genes of the ATP binding cassette (ABC) or the major facilitator (MFS) superfamilies, is the most prominent resistance mechanism, and regulation of their expression by mutations in transcription factors Tac1 and Mrr1 in C. albicans and CgPdr1 in C. glabrata is well established [63] [64] [65] . Point mutations in ERG11, which encodes 14-alpha-demethylase, the target of the azoles, alter drug affinity, and overexpression of ERG11 resulting from mutations in transcription factor UPC2 of C. albicans also confers resistance [66] . In addition, Candida species show genomic plasticity resulting in loss of heterozygosity, increased chromosomal copy number, aneuploidy, or isochromosome formation, which can alter the expression of ERG11 or drug pumps [67] . Finally, biofilm formation that limits drug access is a widespread mechanism that impacts azole and other antifungal drug classes. Due to the diversity of azole resistance mechanisms in Candida species, molecular tools are not yet suitable for the clinical detection of resistance. The exception may be C. glabrata, where azole resistance is closely linked to mutations in the transcription factor PDR1 [68, 69] . DNA sequencing may be the best choice as resistance mutations are broadly dispersed on the gene. However, this is limited in that the linkage between the numerous mutations and overall resistance phenotypes is still emerging.
Azole resistance in A. fumigatus has become a global concern [70] , and the most clinically prevalent mechanism of azole resistance in this species results from an amino acid substitution in Cyp51A [71] . In isolates with environmental exposure to azoles, tandem base pair repeats in the promoter in addition to amino acid substitutions in Cyp51A (TR34/L98H and TR46/ Y121F/T289A) are found [71] [72] [73] . Other potential mechanisms of azole resistance in A. fumigatus have also been described, including overexpression of CYP51B, ABC family transporters and MFS genes, a gain-of-function mutation in the CCATTbinding transcription factor complex subunit HapE, and mutations in the sterol-regulatory element protein SrbA [69, [74] [75] [76] [77] . However, the clinical significance of these other mechanisms of azole resistance is unknown.
The strong association between specific mutations in Cyp51A and azole-resistant phenotypes observed in clinical isolates make these ideal targets for molecular diagnostics. The first real-time multiplexed PCR assay was established to differentiate wild-type CYP51A from 7 mutant alleles at codon 54 encoding either Arg54, Lys54, Val54, Trp54, or Glu54. This multiplexed allele-specific molecular beacon assay was validated on a collection of 48 A. fumigatus clinical and laboratory-derived isolates [78] . Subsequently, a related real-time PCR multiplexed molecular beacon assay was developed to evaluate mutations at codon positions Gly54, Gly138, Met220, and Leu98, as well as the tandem repetition in the gene promoter [79] . A PCR-based TaqMan-based assay was also developed to rapidly identify mutations within the same codons [80] . These real-time systems showed high fidelity compared with DNA sequencing as a gold standard for mutation detection.
An important issue for assessing resistance prevalence is that Aspergillus is often not cultured from respiratory samples and only rarely from blood. Molecular diagnostic tools are highly sensitive and offer a unique opportunity to better study the nature and frequency of azole resistance. Using a nested PCR approach, it was reported that Aspergillus DNA was detected in sputum in 78.9% and 71.4% of patients with ABPA and CPA, compared with 0% and 16.7%, respectively, by culture [81] . In culture-negative, PCR-positive samples, triazole resistance mutations (L98H/TR and M220) were surprisingly detected in 55.1% of samples. The same platform was also used to profile 94 bronchoalveolar lavage fluid (BAL) samples from 87 patients with various underlying diseases in Denmark who were being examined for aspergillosis [82] . A total of 9 CYP51A PCR-positive samples were found to have mutations resulting in amino acid substitutions, although only 2 resistance-associated mutations, M220V and P216L, were found. The TR/L98H mutation was not observed in the BAL collection from Danish patients, although this is the predominant mutation recovered from 8% of Danish environmental A. fumigatus isolates [82] . Similarly, culture and molecular detection of A. fumigatus in 97 respiratory samples from 33 French patients at risk for aspergillosis were compared. Aspergillus detection rates were significantly higher by Aspergillus PCR than by culture in invasive aspergillosis (90.5 vs 42.9%; P < .05) and colonization group (73.7 vs 15.8%; P < .05). PCR found one TR34/L98H along with 5 novel CYP51A mutations, yet no association was established between novel mutations and azole resistance [83] . These studies demonstrate that direct molecular detection of Aspergillus species and azole resistance markers may be useful adjunct tools for surveillance and comprehensive aspergillosis diagnosis.
The AsperGenius multiplex real-time PCR assay (PathoNostics) is a commercially available kit that detects Aspergillus species by targeting the 28S ribosomal RNA, as well as identifies prevalent mutations conferring azole resistance, including TR34, L98H, Y121F, and T289A, directly from BAL samples via melt curve analysis [84] . The diagnostic performance of the AsperGenius assay was initially tested on 37 BAL samples from hematology patients and 40 BAL samples from intensive care unit (ICU) patients using a BAL galactomannan as an Aspergillus gold standard. This assay showed sensitivity, specificity, and positive and negative predictive values of 88.9%, 89.3%, 72.7%, and 96.2%, respectively, for the hematology group and 80.0%, 93.3%, 80.0%, and 93.3%, respectively, in the ICU group. A multicenter study was used to assess the diagnostic performance of the AsperGenius multiplex real-time PCR assay on 201 patient BAL samples and evaluated the relationship between the presence of resistance mutations and azole clinical response [85] . Azole treatment failures were observed in 6 of 8 patients with resistance-associated mutations in contrast to 12 of 45 patients without such mutations; the 6-week mortality was 2.7 times higher in patients with such mutations. Overall, the AsperGenius assay successfully differentiated wild-type from mutant strains with resistance-associated Cyp51A mutations.
CONCLUSIONS
There is an urgent need to rapidly and accurately identify fungal pathogens and assess for resistance to antifungal agents. Current culture-based methodologies are slow and can result in delays in appropriate therapy. In addition, variability observed with in vitro phenotypic susceptibility testing, as can occur with caspofungin against some Candida species, can lead to the failure to adequately distinguish between susceptible and resistant isolates. There is now an overwhelming body of evidence correlating echinocandin resistance with the presence of acquired mutations in the FKS genes encoding the target glucan synthase. Similarly, it is known that the most prominent mechanism conferring azole resistance in A. fumigatus involves mutations in the promoter and coding regions of the CYP51A gene leading to amino acid substitutions in Cyp51A. New rapid non-culture-based molecular technology exists, which facilitates identification of the infecting pathogen, and some also have the ability to detect resistance-associated mutations. Because of their potential to rapidly detect antifungal resistance mechanisms associated and help guide therapy, more work is needed to further establish the clinical utility of these assays. This includes building upon available assays and developing new technologies so that mechanisms other than point mutations associated with echinocandin and azole resistance described above can be detected. In addition, further work correlating the results of molecular testing with clinical outcomes to justify their routine use are needed, as well as work to make them available in more clinical settings rather than just reference laboratories, and possibly as point-of-care devices. It is now time for fungal identification and resistance detection to seriously enter the molecular world and join the ranks of rapid screening platforms used to detect drug-resistant bacteria and viruses.
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